Exact Stock Today

EXAS -  USA Stock  

USD 53.17  0.83  1.54%

Market Performance
0 of 100
Odds Of Distress
Less than 39
Exact Sciences is selling at 53.17 as of the 23rd of May 2022; that is -1.54% down since the beginning of the trading day. The stock's lowest day price was 50.28. Exact Sciences has about a 39 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for Exact Sciences Cor are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 2nd of June 2020 and ending today, the 23rd of May 2022. Click here to learn more.
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin. Exact Sciences operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. The company has 172.32 M outstanding shares of which 13.59 M shares are currently shorted by private and institutional investors with about 7.01 trading days to cover. More on Exact Sciences Cor
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Exact Sciences Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Exact Sciences' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Exact Sciences or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Exact Sciences Cor generated a negative expected return over the last 90 days
Exact Sciences Cor has high historical volatility and very poor performance
The company reported the previous year's revenue of 1.85 B. Net Loss for the year was (745.4 M) with profit before overhead, payroll, taxes, and interest of 1.31 B.
Exact Sciences Cor currently holds about 816.98 M in cash with (198.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.64.
Exact Sciences Cor has a frail financial position based on the latest SEC disclosures
Over 94.0% of the company shares are held by institutions such as insurance companies
Latest headline from finance.yahoo.com: Updated Guidelines from the American Urological Association Include Genomic Assays, such as the Oncotype DX GPS Test, for the First Time in Localized Prostate Cancer Patients - Yahoo Finance
Exact Sciences Fama & French Business Services
Business Services
Fama & French Classification
Exact Sciences Cor SEC Filings
Exact Sciences SEC Filings Security & Exchange Commission EDGAR Reports
ChairmanKevin Conroy  (View All)
Average Analyst Recommendation
Analysts covering Exact Sciences report their recommendations after researching Exact Sciences' financial statements, talking to executives and customers, or listening in on Exact Sciences' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Exact Sciences Cor. The Exact consensus assessment is calculated by taking the average forecast from all of the analysts covering Exact Sciences.
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Exact Sciences Cor based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Exact Sciences Cor financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 3 - FrailDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares150.5 M171.3 M
Fairly Down
Increasing
Slightly volatile
Weighted Average Shares Diluted150.5 M171.3 M
Fairly Down
Increasing
Slightly volatile
Net Cash Flow from Operations(110.3 M)(102.2 M)
Significantly Down
Decreasing
Very volatile
Total Assets7.2 B6.7 B
Significantly Up
Increasing
Slightly volatile
Total Liabilities3.6 B3.3 B
Significantly Up
Increasing
Slightly volatile
Current Assets1.1 B1.4 B
Significantly Down
Increasing
Slightly volatile
Current Liabilities557.9 M517.1 M
Significantly Up
Increasing
Slightly volatile
Total Debt2.6 B2.4 B
Significantly Up
Increasing
Slightly volatile
Gross Margin0.720.74
Fairly Down
Increasing
Very volatile
Asset Turnover0.260.264
Fairly Down
Increasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Exact Sciences' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Financial Strength
Exact Sciences' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Exact Sciences' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Exact Sciences' financial leverage. It provides some insight into what part of Exact Sciences' total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Exact Sciences' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Exact Sciences deploys its capital and how much of that capital is borrowed.
Liquidity
Exact Sciences cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 2.4 B in liabilities with Debt to Equity (D/E) ratio of 0.74, which is about average as compared to similar companies. Exact Sciences Cor has a current ratio of 2.48, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Exact Sciences until it has trouble settling it off, either with new capital or with free cash flow. So, Exact Sciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Exact Sciences Cor sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Exact to invest in growth at high rates of return. When we think about Exact Sciences' use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

(110.31 Million)Share
Exact Sciences Cor (EXAS) is traded on NASDAQ Exchange in USA. It is located in 5505 Endeavor Lane and employs 6,420 people. Exact Sciences is listed under Business Services category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with current market capitalization of 9.16 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Exact Sciences's market, we take the total number of its shares issued and multiply it by Exact Sciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Exact Sciences Cor conducts business under Healthcare sector and is part of Diagnostics & Research industry. The entity has 172.32 M outstanding shares of which 13.59 M shares are currently shorted by private and institutional investors with about 7.01 trading days to cover. Exact Sciences Cor currently holds about 816.98 M in cash with (198.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.64.
Check Exact Sciences Probability Of Bankruptcy
Ownership
Exact Sciences Cor retains a total of 172.32 Million outstanding shares. The majority of Exact Sciences Cor outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Exact Sciences Cor to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Exact Sciences. Please pay attention to any change in the institutional holdings of Exact Sciences Cor as this could imply that something significant has changed or about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation (%)

Check Exact Ownership Details

Exact Stock Price Odds Analysis

What are Exact Sciences' target price odds to finish over the current price? In regard to a normal probability distribution, the odds of Exact Sciences jumping above the current price in 90 days from now is about 92.12%. The Exact Sciences Cor probability density function shows the probability of Exact Sciences stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.6949 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Exact Sciences will likely underperform. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Exact Sciences Cor is significantly underperforming DOW.
  Odds Below 53.17HorizonTargetOdds Above 53.17
7.84%90 days
 53.17 
92.12%
Based on a normal probability distribution, the odds of Exact Sciences to move above the current price in 90 days from now is about 92.12 (This Exact Sciences Cor probability density function shows the probability of Exact Stock to fall within a particular range of prices over 90 days) .

Exact Sciences Historical Income Statement

Exact Sciences Cor Income Statement is one of the three primary financial statements used for reporting Exact's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Exact Sciences Cor revenue and expense. Exact Sciences Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Exact Sciences Selling General and Administrative Expense is relatively stable at the moment as compared to the past year. Exact Sciences reported last year Selling General and Administrative Expense of 1.66 Billion View More Fundamentals

Exact Stock Against Markets

Picking the right benchmark for Exact Sciences stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Exact Sciences stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Exact Sciences is critical whether you are bullish or bearish towards Exact Sciences Cor at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Exact Sciences without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Efficient Frontier Now

   

Efficient Frontier

Plot and analyze your portfolio and positions against risk-return landscape of the market.
All  Next Launch Module

Exact Sciences Corporate Directors

Exact Sciences corporate directors refer to members of an Exact Sciences board of directors. The board of directors generally takes responsibility for the Exact Sciences' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Exact Sciences' board members must vote for the resolution. The Exact Sciences board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Katherine Napier - Independent DirectorProfile
Sally Crawford - Independent DirectorProfile
David Thompson - Lead Independent DirectorProfile
James Doyle - Independent DirectorProfile

Investing Exact Sciences Cor

You need to understand the risk of investing before taking a position in Exact Sciences. The danger of trading Exact Sciences Cor is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Exact Sciences is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Exact Sciences. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Exact Sciences Cor is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Continue to Investing Opportunities. Note that the Exact Sciences Cor information on this page should be used as a complementary analysis to other Exact Sciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Complementary Tools for Exact Stock analysis

When running Exact Sciences Cor price analysis, check to measure Exact Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Exact Sciences is operating at the current time. Most of Exact Sciences' value examination focuses on studying past and present price action to predict the probability of Exact Sciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Exact Sciences' price. Additionally, you may evaluate how the addition of Exact Sciences to your portfolios can decrease your overall portfolio volatility.
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Is Exact Sciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exact Sciences. If investors know Exact will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exact Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Exact Sciences Cor is measured differently than its book value, which is the value of Exact that is recorded on the company's balance sheet. Investors also form their own opinion of Exact Sciences' value that differs from its market value or its book value, called intrinsic value, which is Exact Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exact Sciences' market value can be influenced by many factors that don't directly affect Exact Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exact Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Exact Sciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exact Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.